Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NNVC
Upturn stock ratingUpturn stock rating

NanoViricides Inc (NNVC)

Upturn stock ratingUpturn stock rating
$1.47
Last Close (24-hour delay)
Profit since last BUY-10.37%
upturn advisory
WEAK BUY
BUY since 21 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: NNVC (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $6.5

1 Year Target Price $6.5

Analysts Price Target For last 52 week
$6.5 Target price
52w Low $0.94
Current$1.47
52w High $2.34

Analysis of Past Performance

Type Stock
Historic Profit -59.35%
Avg. Invested days 25
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 23.63M USD
Price to earnings Ratio -
1Y Target Price 6.5
Price to earnings Ratio -
1Y Target Price 6.5
Volume (30-day avg) 1
Beta 0.96
52 Weeks Range 0.94 - 2.34
Updated Date 08/15/2025
52 Weeks Range 0.94 - 2.34
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.69

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -57.38%
Return on Equity (TTM) -99.84%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 18155948
Price to Sales(TTM) -
Enterprise Value 18155948
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -1.11
Shares Outstanding 16072000
Shares Floating 15504658
Shares Outstanding 16072000
Shares Floating 15504658
Percent Insiders 3.53
Percent Institutions 7.94

ai summary icon Upturn AI SWOT

NanoViricides Inc

stock logo

Company Overview

overview logo History and Background

NanoViricides, Inc. was founded in 2003 and is headquartered in Shelton, Connecticut. The company focuses on developing antiviral therapies based on its proprietary nanoviricideu00ae technology.

business area logo Core Business Areas

  • Nanoviricides Drug Development: The company develops nanoviricides, which are specifically designed antiviral drugs, for various viral diseases.
  • Nanobiotherapeutic Platform Technology: NanoViricides owns its novel nanobiotherapeutic platform technology and is exploring additional fields of application in nanomedicines.

leadership logo Leadership and Structure

Dr. Anil Diwan is the Executive Chairman, President, and CEO. The company operates with a focused management team and scientific advisory board guiding its research and development efforts.

Top Products and Market Share

overview logo Key Offerings

  • Herpes Nanoviricides: The company is developing nanoviricides for herpes simplex virus (HSV-1 and HSV-2) infections. Market share data is unavailable as the product is still in preclinical and early clinical stages. Competitors: GlaxoSmithKline (GSK), Pfizer (PFE), Novartis (NVS).
  • COVID-19 Nanoviricides: Development of nanoviricides for treating COVID-19. Market share data is unavailable as the product is still in preclinical and early clinical stages. Competitors: Pfizer (PFE), Merck (MRK), Gilead Sciences (GILD).

Market Dynamics

industry overview logo Industry Overview

The antiviral drug market is driven by the increasing prevalence of viral infections and the growing demand for effective treatments. The market is characterized by intense competition and regulatory scrutiny.

Positioning

NanoViricides is positioned as an innovative developer of novel antiviral therapies using its nanoviricide technology. Its competitive advantage lies in its targeted drug delivery system.

Total Addressable Market (TAM)

The global antiviral drugs market is expected to reach approximately $60 billion by 2028. NanoViricides aims to capture a share of this market through its innovative nanoviricide technology.

Upturn SWOT Analysis

Strengths

  • Proprietary nanoviricide technology platform
  • Targeted drug delivery system
  • Potential for broad-spectrum antiviral activity
  • Focused management team

Weaknesses

  • Limited financial resources
  • Early stage of product development
  • High regulatory hurdles
  • No currently marketed products

Opportunities

  • Growing demand for antiviral therapies
  • Potential for partnerships and collaborations
  • Expansion into new viral disease targets
  • Government funding opportunities

Threats

  • Competition from established pharmaceutical companies
  • Clinical trial failures
  • Regulatory delays
  • Patent infringement

Competitors and Market Share

competitor logo Key Competitors

  • PFE
  • MRK
  • GILD

Competitive Landscape

NanoViricides faces significant competition from established pharmaceutical companies with greater resources and marketed products. NanoViricides differentiates itself through its novel nanoviricide technology.

Growth Trajectory and Initiatives

Historical Growth: NanoViricides has not yet achieved significant revenue growth due to its focus on research and development.

Future Projections: Future growth is dependent on the successful development and commercialization of its nanoviricide products. Analyst estimates are highly speculative.

Recent Initiatives: Recent initiatives include advancing clinical trials for its lead nanoviricide candidates and seeking partnerships for further development and commercialization.

Summary

NanoViricides is a high-risk, high-reward biotechnology company focused on developing antiviral therapies. Its proprietary nanoviricide technology offers potential advantages, but the company faces significant financial and regulatory challenges. Success depends on positive clinical trial outcomes and securing funding or partnerships. The lack of current products makes the company susceptible to speculative trading.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Industry reports
  • Market research reports

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor. Market share figures are estimates and may not be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About NanoViricides Inc

Exchange NYSE MKT
Headquaters Shelton, CT, United States
IPO Launch date 2005-10-26
Executive Chairman, President, CEO & Secretary Dr. Anil R. Diwan Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 7
Full time employees 7

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.